Xuanzhu Biopharm set for spin-off in Hong Kong IPO
轩竹生物转战港股上市 母企四环医药转型减负

The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines.
轩竹生物拥有一款已经上市获批的药物和两款递交上市申请的药物，但同类产品竞争均相当激烈。